Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 4/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.38 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1445231 | 0.81 | SMN1; SMN2 (0.55) | MIFFYNL3MBTL1BRAFNPC1 | |
| SCHEMBL14804510 | 0.77 | MIF (0.42) | MIF | |
| SCHEMBL13165650 | 0.73 | LMNA (0.52) | DYRK1AFYNL3MBTL1PIP4K2APIP4K2B | |
| SCHEMBL2598684 | 0.72 | MIF (0.44) | MIF | |
| SCHEMBL19706539 | 0.68 | DYRK1A (0.48) | DYRK1ACLK1CLK2DYRK2CLK4 | |
| SCHEMBL19706498 | 0.68 | PIK3CG (0.51) | DYRK1ACLK1CLK2DYRK2CLK4 | |
| SCHEMBL31311343 | 0.67 | HSD17B10 (0.53) | DYRK1AL3MBTL1GSK3BNPC1RAB9A | |
| SCHEMBL7668126 | 0.67 | HSD17B10 (0.53) | DYRK1AL3MBTL1GSK3BNPC1RAB9A | |
| SCHEMBL13692813 | 0.67 | LMNA (0.61) | DYRK1ACLK1CLK2DYRK2CLK4 | |
| SCHEMBL1444763 | 0.66 | MIF (0.65) | CLK4MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | claimed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | claimed |
| EP-2480235-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | University Of Louisville Research Foundation, Inc. (US) | 2012-08-01 | — | — | EP | claimed |
| WO-2011038234-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-03-31 | — | — | WO | claimed |
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2018-01-11 | — | — | US | disclosed |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2015-12-24 | — | — | US | disclosed |
| US-9162987-B2 | Iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (MIF)-implicated diseases and conditions | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9155790-B2 | Methods and compositions for modulating ocular damage | University of Lousiville Research Foundation, Inc. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130177552-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | ADVANCED CANCER THERAPEUTICS, LLC | 2013-03-28 | — | — | US | disclosed |
| EP-2480235-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | University Of Louisville Research Foundation, Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011146824-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011038234-A2 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2011-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079361-A1 | NOVEL IODO PYRIMIDINE DERIVATIVES USEFUL FOR THE TREATMENT OF MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS | MIF, MSR1, CCL2 | DYRK1A 3578/4885CLK1 3958/4885CLK2 3141/4885 |
| US-20130177552-A1 | METHODS AND COMPOSITIONS FOR MODULATING OCULAR DAMAGE | MIF, MMP1, CXCL12 | DYRK1A 4240/4885CLK1 2811/4885CLK2 3119/4885 |
| US-20180009764-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | MIF, MSR1, CCL2 | DYRK1A 3709/4885CLK1 3432/4885CLK2 2583/4885 |
| US-20150368207-A1 | METHOD FOR TREATING MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF)-IMPLICATED DISEASES AND CONDITIONS WITH IODO PYRIMIDINE DERIVATIVES | MIF, MSR1, CCL2 | DYRK1A 3709/4885CLK1 3432/4885CLK2 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.